Merck cutting 8,500 jobs in massive R&D, commercial shakeup
This article was originally published in Scrip
Executive Summary
Merck & Co. is cutting 8,500 jobs and jettisoning some research and development programs as the big drug maker refocuses its strategy and moves to save $2.5 billion a year in annual costs.
You may also be interested in...
Merck’s Perlmutter Is Retiring, Handing Over Keytruda To Li
Merck Research Laboratories president Roger Perlmutter returned to the company when its R&D was at a crossroads. Now he is retiring and handing the company’s post-Keytruda growth over to SVP Dean Li.
Baxter's Advate helps prevent bleeding in one-year study of hemophiliacs
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Bresch is looking to do a sizable deal
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.